Should I buy or sell Phio Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHIO shares. View PHIO analyst ratings or view top-rated stocks .

What is Phio Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12-month target prices for Phio Pharmaceuticals' shares. Their PHIO share price targets range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 525.1% from the stock's current price. View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts .

How have PHIO shares performed in 2024?

Phio Pharmaceuticals' stock was trading at $0.76 at the beginning of 2024. Since then, PHIO shares have decreased by 15.8% and is now trading at $0.6399. View the best growth stocks for 2024 here .

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 21,400 shares, a decline of 87.9% from the March 15th total of 176,600 shares. Based on an average trading volume of 314,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the company's shares are sold short. View Phio Pharmaceuticals' Short Interest .

When is Phio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PHIO earnings forecast .

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its earnings results on Wednesday, November, 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.03.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX) , CymaBay Therapeutics (CBAY) , Ocugen (OCGN) , Akero Therapeutics (AKRO) , Boxlight (BOXL) , Evofem Biosciences (EVFM) , Fulcrum Therapeutics (FULC) , Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST) .

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PHIO Stock Alerts

$0.64

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.61
▼
$0.65
50-Day Range: $0.64
▼
$1.08
52-Week Range: $0.50
▼
$6.85

Volume: 28,516 shs
Average Volume: 81,154 shs
Market Capitalization: $2.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Phio Pharmaceuticals alerts:

Phio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 525.1% Upside
$4.00 Price Target
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$2,275 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.43 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Phio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Phio Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Phio Pharmaceuticals has recently decreased by 87.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Phio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Phio Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHIO.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Phio Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for PHIO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,275.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.77% of the stock of Phio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Phio Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phio Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Phio Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Phio Pharmaceuticals Stock (NASDAQ:PHIO)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

PHIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHIO Stock News Headlines

April 16, 2024 | globenewswire.com

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

April 11, 2024 | globenewswire.com

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | finance.yahoo.com

National Spotlight Features Phio’s Innovative RNAi Technology Platform

April 3, 2024 | globenewswire.com

National Spotlight Features Phio's Innovative RNAi Technology Platform

April 2, 2024 | globenewswire.com

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

March 21, 2024 | finance.yahoo.com

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

March 13, 2024 | globenewswire.com

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 10, 2024 | morningstar.com

Phio Pharmaceuticals Corp PHIO

March 6, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)

March 6, 2024 | finance.yahoo.com

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

March 6, 2024 | globenewswire.com

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

February 14, 2024 | uk.finance.yahoo.com

February 6, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)

January 31, 2024 | finance.yahoo.com

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

December 19, 2023 | msn.com

Phio Pharmaceuticals files to sell 4.42M shares of common stock for holders

December 7, 2023 | msn.com

Why Phio Pharmaceuticals Stock Is Nosediving

December 7, 2023 | finance.yahoo.com

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

November 10, 2023 | finanznachrichten.de

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 10, 2023 | msn.com

Phio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29

November 9, 2023 | finance.yahoo.com

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 9, 2023 | finance.yahoo.com

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

November 3, 2023 | finanznachrichten.de

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

November 3, 2023 | finance.yahoo.com

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

October 12, 2023 | finance.yahoo.com

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 12, 2023 | finance.yahoo.com

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

See More Headlines

Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PHIO
CUSIP: N/A
CIK: 1533040
Web: phiopharma.com
Phone: (508) 767-3861
Fax: 508-767-3862
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +525.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -134.66%
Return on Assets: -105.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.70
Quick Ratio: 5.71

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.06 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 4,590,000
Free Float: 4,557,000
Market Cap: $2.94 million
Optionable: Not Optionable
Beta: 1.44

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Robert J. Bitterman (Age 73)
President, CEO & Chairman
Comp: $141.46k
Ms. Caitlin Kontulis (Age 38)
VP of Finance & Administration and Secretary
Ms. Linda M. Mahoney
Senior Vice President of Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

PHIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Phio Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHIO shares.
View PHIO analyst ratings or view top-rated stocks.
What is Phio Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 12-month target prices for Phio Pharmaceuticals' shares. Their PHIO share price targets range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 525.1% from the stock's current price.
View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts.
How have PHIO shares performed in 2024?: Phio Pharmaceuticals' stock was trading at $0.76 at the beginning of 2024. Since then, PHIO shares have decreased by 15.8% and is now trading at $0.6399.
View the best growth stocks for 2024 here.
Are investors shorting Phio Pharmaceuticals?: Phio Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 21,400 shares, a decline of 87.9% from the March 15th total of 176,600 shares. Based on an average trading volume of 314,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the company's shares are sold short.
View Phio Pharmaceuticals' Short Interest.

When is Phio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PHIO earnings forecast.
How were Phio Pharmaceuticals' earnings last quarter?: Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its earnings results on Wednesday, November, 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.03.
What other stocks do shareholders of Phio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).
How do I buy shares of Phio Pharmaceuticals?: Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHIO) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

Phio Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Phio Pharmaceuticals Stock (NASDAQ:PHIO)

PHIO Stock Price History

PHIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

PHIO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™